GH in fibromyalgia trials: a selected subgroup, not a sermorelin claim

The subgroup and the medicine matter

Some older studies reported symptom improvement with recombinant growth hormone in selected people with severe fibromyalgia and low IGF-1. That is narrower than a claim that GH-related peptides treat fibromyalgia. The trials did not test sermorelin, and their eligibility, duration and background care are central to interpretation. ^{[1] [2]} A reader should not dismiss the research because it is small, but neither should a provider borrow it to promise pain relief from a different preparation. The useful question is what was actually tested and how closely that experiment matches the person and intervention now being discussed.

The nine-month randomized trial

Bennett and colleagues enrolled fifty women with fibromyalgia and low IGF-1 into a randomized, double-blind study of daily subcutaneous GH or placebo for nine months. The reported treatment and control outcome groups included twenty-two and twenty-three women. GH was adjusted using monthly IGF-1 review. At nine months, questionnaire and tender-point outcomes favored GH, and global improvement was reported by fifteen treated participants versus six controls. ^[1] The delayed response, often around six months, should remain attached. This was not a rapid-response trial and does not validate a claim of immediate relief after a peptide prescription.

The harms belong beside the benefit

Carpal-tunnel symptoms were more common with GH in that trial, seven participants versus one with placebo, and symptoms worsened after treatment was discontinued. ^[1] Those findings change the benefit-harm discussion. A favorable questionnaire result cannot be interpreted without the treatment burden and adverse effects. The small sample also limits precision about uncommon or longer-term problems. A prospective patient should not infer safety from a natural-signaling description or assume that a different GH-related product avoids the trial’s uncertainties. The actual preparation and the reason for using it need an individualized clinical assessment.

For the broader context, read how to interpret IGF-1 results.

A larger study changed phases over time

Cuatrecasas and colleagues later enrolled 120 people with severe fibromyalgia and low IGF-1, sixty per group, using 0.006 mg/kg daily subcutaneous GH or placebo initially. Existing fibromyalgia medicines continued. The blinded comparison lasted six months; the placebo group then changed to GH during an open phase, with later follow-up after stopping treatment through month eighteen. ^[2] The design matters as much as the duration. An eighteen-month study is not automatically eighteen months of randomized placebo comparison, and the continued background treatment means the intervention was an addition rather than a demonstrated replacement for established care.

Do not call all eighteen months placebo-controlled

The later report describes fewer positive tender points in fifty-three percent of the earlier-GH group versus thirty-three percent in the delayed group, and more-than-fifty-percent pain-score improvement in 39.1 versus 22.4 percent. ^[2] These figures need the changing-phase design attached rather than being presented as a simple long-term placebo-controlled effect. They are not cure rates. The reader should also distinguish a symptom-scale improvement from complete recovery or proof of a particular biological cause. A study can provide useful evidence of a possible clinical effect while leaving major questions about generalizability and practical treatment decisions unresolved.

Low IGF-1 did not equal one uniform diagnosis

A separate multicenter assessment studied 493 women with severe fibromyalgia; 169, or 34.2 percent, had IGF-1 at or below 150 micrograms per liter. Additional endocrine testing was performed in the low-IGF-1 group. ^[3] This illustrates selection, not proof that every person with fibromyalgia has GH deficiency. A laboratory threshold used to organize a study should not become a universal diagnostic rule. The reader needs the actual clinical context and appropriate testing, especially when a nonspecific symptom profile overlaps with several conditions. An isolated value cannot establish that the correct next step is hormone-related treatment.

What these studies cannot decide

These studies do not establish whether a contemporary compounded-sermorelin formulation improves fibromyalgia, whether a blend is preferable or which online service provides the best clinical outcome. ^{[1] [2]} Those would require different evidence. Replacing the studied medicine with a releasing analogue changes the intervention, even if both relate to GH biology. The reported results also cannot settle long-term safety or the best approach for every patient with chronic pain. A service comparison should not use a trial’s existence as a substitute for explaining the actual prescription being proposed and the uncertainty that remains.

A real symptom needs coordinated care

For a person living with persistent pain and fatigue, the clinical discussion should remain coordinated with the professionals managing the condition. Bring prior evaluations, laboratory reports and the current medicine list. Ask whether any endocrine concern requires further assessment and how that work fits the existing care plan. Do not stop effective treatment to pursue a peptide-marketing timeline. The research described here maintained a defined clinical framework, and in the larger trial background treatment continued. ^[2] A consumer service that removes those conditions from its story is presenting a different intervention from the one the paper actually evaluated.

Keep the distinction clear with adverse events and monitoring.

The service decision should remain separate

The defensible conclusion is that selected GH trials produced symptom signals worth understanding, with meaningful limitations and adverse effects. They are not proof that low IGF-1 explains all fibromyalgia or that sermorelin should be purchased for pain relief. If an appropriate clinician raises a hormone-related question, clarify the diagnosis, medicine, monitoring and reassessment point before comparing service costs. A clear care agreement may help a patient navigate a complex decision, but it cannot make one peptide inherit another medicine’s trial results. The evidence should narrow the claim while preserving the real clinical question.

For a separate practical comparison, see Defy Medical review; a product review does not turn this study into a treatment recommendation.